STAT+: Psilocybin data could be good enough for approval

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good day! Today: A look at growing GLP-1 competition in China, a drug reviewed as part of the FDA’s shiny new fast-track voucher hits a roadblock, and Secretary Kennedy’s vaccine overhaul gets a hard look in federal court.

Also, psilocybin may be headed for approval despite mildly anticlimactic remission rates, and Ocular’s wet AMD drug does .… fine.

Continue to STAT+ to read the full story…